A systematic review and meta-analysis of randomized controlled trials, juxtaposing the control of glycemia and blood pressure between large dose empagliflozin and placebo among type 1 diabetes patients.

Such a small sample size decreases the statistical power and also reduces the chance of generalizability of any nominally significant statistical finding.[ 22 ] Therefore, to increase the statistical power of individual trials on empagliflozin (by decreasing the standard error of the weighted average effect size), its important to summarize the findings by meta-analysis,[ 23 ] as we have attempted in this paper.

also in 7,732 other papers